Advertisement

Topics

Latest "Therapure Biopharma" News Stories

04:13 EST 16th December 2017 | BioPortfolio

Here are the most relevant search results for "Therapure Biopharma" found in our extensive news archives from over 250 global news sources.

More Information about Therapure Biopharma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Therapure Biopharma for you to read. Along with our medical data and news we also list Therapure Biopharma Clinical Trials, which are updated daily. BioPortfolio also has a large database of Therapure Biopharma Companies for you to search.

Showing "Therapure Biopharma" News Articles 1–25 of 2,500+

Extremely Relevant

Therapure Biopharma announces spin off and sale of CDMO business

Therapure Biopharma announced that a joint venture between 3SBio, a global biotechnology company, and CPE Funds (investment funds advised by CITICPE) has entered into an agreement to acquire Therapure’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market for $290 million, subject to certain adjustments. The […] ...


Therapure Biopharma to divest CDMO business for $290m

A joint venture (JV) between 3SBio and CPE Funds has entered an asset purchase agreement to purchase Canadian biologics manufacturer Therapure Biopharma’s contract development and manufacturing (CDMO) business, Therapure Biomanufacturing, for $290m.

Therapure Biopharma Inc. Announces Spin Off and Sale of Contract Development and Manufacturing Business for US$290 Million

Sunday, September 3rd 2017 at 11:11am UTC CDMO Purchase by Joint Venture Between 3SBio Inc. and CPE Funds Further Strengthens Biomanufacturing Growth Opportunities The Catalyst Capital Group Inc. to Retain and Focus on Commercialization of Plasma Products Under Separate Entity MISSISSAUGA, Ontario–(BUSINESS WIRE)– Therapure Biopharma Inc. (“Therapure” or the “Company”) today an...


Therapure Biopharma to sell CDMO business to 3SBio

Canada-based Therapure Biopharma has agreed to divest its contract development and manufacturing (CDMO) business to a joint venture between Chinese biotechnology company 3SBio and CPE Funds for $290m.

Therapure's development, manufacturing business purchased by 3SBio, CPE JV

Therapure Biopharma's contract development and manufacturing business and rights to plasma products and technology in China w -More- 

Relevant

3SBio acquiring biomanufacturing business of Therapure

China-based biotech 3SBio (HKG: 1530) has entered into an agreement to acquire Canadian firm Therapure…

China’s 3SBio enters North American market through $290m Therapure buy

3SBio will leverage Therapure’s downstream purification expertise to bolster its own biologics portfolio while expanding its contract biomanufacturing business and global presence.

Therapure Biopharma Inc. Ranks No. 115 on the 2017 PROFIT 500 – its 4th Consecutive Year on the List

– Canadian Business unveils 29th annual list of Canada’s Fastest-Growing Companies – Canadian Business and PROFIT recently ranked Therapure Biopharma Inc. (“Therapure” or the “Company”) No. 115 on the 29th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies. Published in the October issue of Maclean’s magaz...

Therapure Biopharma Inc. Announces Spin Off and Sale of Contract Development and Manufacturing ...

The Catalyst Capital Group Inc. to Retain and Focus on Commercialization of Plasma Products Under Separate Entity Read more...

Therapure Biopharma Inc. Wins the Mississauga Board of Trade’s 2017 Business Awards of Excellence

Therapure Biopharma Inc. announces that it is the recipient of the Mississauga Board of Trade’s (MBOT’s) 2017 Business Awards of Excellence. Hundreds of members and honoured guests were on hand for this sold out event, held at the Mississauga Convention Centre on Thursday, November 16, 2017. In winning the MBOT award, Therapure demonstrated: ...

Chinese biopharma 3SBio in $290 mln deal for unit of Canada's Therapure

The deal, being done through a venture set up by 3SBio and CITIC Private Equity investment, fits with a push by Chinese drugmakers and biopharmaceutical companies to increase their role in the global market. "3SBio's global expansion strategy is now on fast track," Jing Lou, chairman of 3SBio, said in a statement on Sunday.

Therapure Biopharma Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryTherapure Biopharma Inc Therapure is a biopharmaceutical company that offers research and development services. The company's activities include manufacture, development, purification, and packaging of therapeutic proteins and followon biologics. It operates through its division therapure biomanufacturing, therapure innovations and therapure biologics. Therapure's therapure biomanufacturing...

3SBio to acquire Therapure's CDMO business

3SBio Pays $290 Million for Therapure's CDMO Biz

  Life Sciences Jobs   ...

3SBio Acquires Therapure for $290M

Accelerates expansion of its global biologics platform

3SBio Acquires CDMO Business From Canada's Therapure For $290 Million

  Life Sciences Jobs   ...

Therapure Ranks No. 115 On The 2017 PROFIT 500 ??? Its 4th Consecutive Year On The List

  Life Sciences Jobs   ...

3SBio snaps up Therapure CDMO for $290M

The Chinese company looks to the west for further expansion into drug development and manufacturing.

Therapure Biopharma Inc. Announces Spin Off and Sale of Contract Development and Manufacturing Business for US$290 Million

CDMO Purchase by Joint Venture Between 3SBio Inc. and CPE Funds Further Strengthens Biomanufacturing Growth Opportunities The Catalyst Capital Group Inc. to Retain and Focus on Commercialization of Plasma Products Under Separate Entity Therapure Biopharma Inc. (“Therapure” or the “Company”) today announced that a joint venture between ...

KBI Biopharma: How to stand out in the CMO space

KBI Biopharma is a CMO focused exclusively on biologics. Bernardo Estupinan-Gaisbauer, Vice President – Business Development at KBI Biopharma, discusses their strategy for partnering, and the challenges of staying competitive in the CMO sector.

#jobs #lifescience Head of Quality Assurance, Biopharma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Head of Quality Assurance, Biopharma .MA-Boston, Based in the Greater Boston Area, we are a growing biopharma looking for a Senior Director, QA with GxP experience to develop … Continue reading → Cet article #jobs #lifescience Head of Quality Assurance, Biopharma e...

Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading ...

MELBOURNE, AUSTRALIA--(Marketwired - August 30, 2017) -Propanc Biopharma Inc.( OTCQB : PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical Read more...

Vitality Biopharma Closes $1 Million Private Placement

LOS ANGELES, CA -- (Marketwired) -- 08/02/17 -- Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoi...

Vitality Biopharma to Present at The MoneyShow San Francisco Conference

LOS ANGELES, CA -- (Marketwired) -- 08/23/17 -- Vitality Biopharma, Inc. (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoi...

Critical Survey: Galena Biopharma (GALE) vs. Its Peers

Galena Biopharma is one of 116 publicly-traded companies in the "Pharmaceuticals" industry, but how does it compare to its peers? We will compare Galena Biopharma to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation. 20.5% of Galena Biopharma shares are owned by institutional investors.


Quick Search
Advertisement
 

News Quicklinks